Medication info
Rozet Plus Tablet

Rozet Plus Tablet

Prescription medicationTabletOral
Ingredient · strength
Losartan Potassium›50mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Dongkwang Pharmaceutical Co., Ltd.
Appearance
Yellow oval film-coated tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 200607657 · Notified 2006.09.12

Summary

Main use
Treatment of hypertension not controlled by monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding 100 mg losartan potassium/25 mg hydrochlorothiazide daily are not recommended. The maximum blood pressure-lowering effect generally occurs around 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this medicine only when the expected effect has not been achieved with monotherapy. 1. Substitution therapy: Concomitant therapy with individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of administration, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of administration, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with 25 mg hydrochlorothiazide once daily, or who have hypokalemia despite blood pressure control at this dose: Treatment may be initiated with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of administration, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment The usual dose should be administered when creatinine clearance is 30 mL/min or higher. Administration is not recommended in patients with more severe renal impairment, as loop diuretics are preferable to thiazide drugs in these patients. ○ Patients with hepatic impairment Administration is not recommended in patients with hepatic impairment requiring dose adjustment, since the initial dose of losartan potassium for such patients, 25 mg, cannot be administered as this combination medicine.
Child dose
Under 18 years: The losartan-hydrochlorothiazide combination has not been used in children and adolescents; therefore, do not administer it to children or adolescents.

Ingredients

Manufacturer
Dongkwang Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled by monotherapy

  • Hypertension
View approved original text

This medication is used to effectively control blood pressure in hypertensive patients where blood pressure is not adequately controlled with monotherapy.

How to take

Adult dose

○ Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding 100 mg losartan potassium/25 mg hydrochlorothiazide daily are not recommended. The maximum blood pressure-lowering effect generally occurs around 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this medicine only when the expected effect has not been achieved with monotherapy. 1. Substitution therapy: Concomitant therapy with individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of administration, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of administration, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with 25 mg hydrochlorothiazide once daily, or who have hypokalemia despite blood pressure control at this dose: Treatment may be initiated with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of administration, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment The usual dose should be administered when creatinine clearance is 30 mL/min or higher. Administration is not recommended in patients with more severe renal impairment, as loop diuretics are preferable to thiazide drugs in these patients. ○ Patients with hepatic impairment Administration is not recommended in patients with hepatic impairment requiring dose adjustment, since the initial dose of losartan potassium for such patients, 25 mg, cannot be administered as this combination medicine.

Child dose

Under 18 years: The losartan-hydrochlorothiazide combination has not been used in children and adolescents; therefore, do not administer it to children or adolescents.

Precautions

This medication can severely harm a fetus if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. This drug should not be administered to patients with certain allergies, severe renal impairment, severe hepatic impairment, or to women who are pregnant or may become pregnant. Caution should be exercised when using this medication in patients with very low blood pressure, renal vascular issues, weak liver function, hyperuricemia, or gout. Symptoms such as dizziness, hypotension, and electrolyte imbalance may occur during treatment; therefore, attention should be paid to these symptoms. Due to the hydrochlorothiazide component, electrolyte imbalances can occur, so regular blood tests are recommended, and immediate consultation with a doctor is necessary in cases of severe vomiting or diarrhea. This drug may increase the risk of skin cancer due to heightened sensitivity to sunlight, so sun exposure should be avoided, and any skin abnormalities should be reported to a doctor immediately. The combination of this drug with other antihypertensive drugs or potassium supplements may dangerously alter serum potassium levels, thus medical guidance must be followed. There may be dizziness or drowsiness when driving or operating machinery, so caution is advised, particularly at the beginning of treatment or when there is a change in dosage. If any abnormal symptoms or allergic reactions occur during treatment, use should be discontinued immediately and medical advice sought. There is no confirmed safety for use in children and adolescents, so use is not recommended.

Side effects

  • Craniosynostosis
  • Anuria
  • Hypotension
  • Renal failure
  • Death
  • Abdominal pain
  • Edema
  • Palpitations
  • Back pain
  • Dizziness
Show 140 more
  • Cough
  • Sinusitis
  • Upper respiratory infection
  • Rash
  • Angioedema
  • Skin shedding phenomenon
  • Hemolysis
  • Chest pain
  • Facial edema
  • Fever
  • Orthostatic hypotension
  • Syncope
  • Angina pectoris
  • Arrhythmia
  • Cerebrovascular accident
  • Hypotension
  • Myocardial infarction
  • Secondary AV block
  • Anorexia
  • Constipation
  • Toothache
  • Dry mouth
  • Dyspepsia
  • Flatulence
  • Gastritis
  • Vomiting
  • Apathy
  • Anemia
  • Gout
  • Arm pain
  • Arthralgia
  • Arthritis
  • Fibromyalgia
  • Hip pain
  • Joint swelling
  • Knee pain
  • Limb pain
  • Muscle cramps
  • Muscle weakness
  • Musculoskeletal pain
  • Myalgia
  • Shoulder pain
  • Muscle rigidity
  • Anxiety
  • Anxiety disorder
  • Ataxia
  • Confusion
  • Depression
  • Nightmares
  • Sensory impairment
  • Insomnia
  • Decreased libido
  • Memory impairment
  • Migraine
  • Neuritis
  • Panic disorder
  • Sensory disturbances
  • Peripheral neuropathy
  • Sleep disorders
  • Drowsiness
  • Tremor
  • Dizziness
  • Shortness of breath
  • Epistaxis
  • Nasal congestion
  • Pharyngeal discomfort
  • Respiratory congestion
  • Rhinitis
  • Venous sinus disorder
  • Chest discomfort
  • Alopecia
  • Dermatitis
  • Skin dryness
  • Petechiae
  • Erythema
  • Flushing
  • Photosensitivity reaction
  • Pruritus
  • Sweating
  • Urticaria
  • Blurred vision
  • Ocular pain
  • Burning sensation
  • Conjunctivitis
  • Visual impairment
  • Taste disturbance
  • Tinnitus
  • Erectile dysfunction
  • Nocturia
  • Frequent urination
  • Urinary tract infection
  • Weakness
  • Pancreatitis
  • Jaundice
  • Sialadenitis
  • Cramps
  • Gastrointestinal irritation
  • Aplastic anemia
  • Agranulocytosis
  • Leukopenia
  • Hemolytic anemia
  • Thrombocytopenia
  • Purpura
  • Necrotizing vasculitis
  • Fever
  • Pneumonia
  • Pulmonary edema
  • Acute respiratory distress syndrome
  • Hyperglycemia
  • Diabetes
  • Muscle cramps
  • Agitation
  • Renal failure
  • Renal impairment
  • Interstitial nephritis
  • Skin and mucous membrane syndrome
  • Erythema multiforme
  • Toxic epidermal necrolysis
  • Temporary blurred vision
  • Yellow vision
  • Acute myopia
  • Acute angle-closure glaucoma
  • Choroidal exudate
  • Hypotension
  • Tachycardia
  • Hypokalemia
  • Hypochloremia
  • Hyponatremia
  • Dehydration
  • Cardiac arrhythmia
  • Vasculitis
  • Angioedema
  • Thrombocytopenia
  • Hepatitis
  • Intestinal vascular edema
  • Dry cough
  • Erythroderma
  • Hyperkalemia
  • Hyponatremia
  • Rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a special container that does not allow light to enter. Additionally, to maintain the efficacy of the medication, it should be stored at a temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Yellow oval film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.